Results 31 to 40 of about 79,311 (270)

Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity

Cancer Medicine, 2023
Objective Irinotecan is a useful anticancer drug for colorectal cancer treatment. UGT1A1*28 and *6 gene polymorphisms are known risk factors for irinotecan‐associated toxicity.
Kou Kanesada, Ryouichi Tsunedomi, Shoichi Hazama, Hiroyuki Ogihara, Yoshihiko Hamamoto, Yoshitaro Shindo, Hiroto Matsui, Yukio Tokumitsu, Shin Yoshida, Michihisa Iida, Nobuaki Suzuki, Shigeru Takeda, Tatsuya Ioka, Hiroaki Nagano   +13 more
doaj   +1 more source

Irinotecan (CPT-11) Treatment Induces Mild Gonadotoxicity

Frontiers in Reproductive Health, 2022
Background:Gonadal toxicity following chemotherapy is an important issue among the population of young cancer survivors. The inhibitor of DNA topoisomerase I, irinotecan (CPT-11), is widely used for several cancer types.
Mattan Levi, Mattan Levi, Irit Ben-Aharon, Irit Ben-Aharon, Ruth Shalgi   +4 more
doaj   +1 more source

Protective role of Lactobacillus plantarum A7 against irinotecan-induced genotoxicity [PDF]

Avicenna Journal of Phytomedicine, 2016
Objective: Irinotecan is a botanical derivative and an anti-cancer drug with cytotoxic and genotoxic effects. The present study evaluated the effect of Lactobacillus plantarum A7 on the genotoxic activity of irinotecan in a hepatocellular carcinoma cell ...
Soheila Sepahi, Abbas Jafarian-Dehkordi, Maryam Mirlohi, kobra shirani, Mahmoud Etebari   +4 more
doaj  

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial

Cancer Communications, 2019
Background The 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX) regimen is the standard first-line treatment for metastatic colorectal cancer (mCRC), however, the optimal second-line regimen for KRAS wild-type mCRC patients is still investigational ...
Yuankai Shi, Jin Li, Jianming Xu, Yan Sun, Liwei Wang, Ying Cheng, Wei Liu, Guoping Sun, Yigui Chen, Li Bai, Yiping Zhang, Xiaohui He, Yi Luo, Zhehai Wang, Yunpeng Liu, Qiang Yao, Yuhong Li, Shukui Qin, Xiaohua Hu, Feng Bi, Rongsheng Zheng, Xuenong Ouyang   +21 more
doaj   +1 more source

Successful Treatment of Irinotecan-Induced Muscle Twitching: A Case Report

Clinical Medicine Insights: Case Reports, 2023
Irinotecan, a topoisomerase I inhibitor, is commonly used in the treatment of advanced colorectal cancer. Its adverse effects include delay diarrhea, severe myelosuppression, and cholinergic-like symptoms.
Yu-Ting Shun, Hsien-Yung Lai, Yi-Ting Chuang, Hsuen-Fu Lin   +3 more
doaj   +1 more source

Characterization of mucin 2 expression in colorectal cancer with and without chemotherapies, in vivo and in vitro study

Journal of Umm Al-Qura University for Medical Science, 2021
Background: Colorectal cancer (CRC) is the third and second most prevalent cancer affecting males and females, respectively. 5-fluorouracil (5-FU) and irinotecan are the main chemotherapies for CRC.
Hussain Almasmoum
doaj   +1 more source

Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. [PDF]

, 2016
Sarcomas are a heterogeneous group of mesenchymal malignancies. In recent years, studies have demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of sarcomas.
DuBois, Steven G, Matthay, Katherine K, Vo, Kieuhoa T   +2 more
core   +1 more source

The potential role and application of PARP inhibitors in cancer treatment [PDF]

, 2009
Background: Since many anti-cancer agents act by inflicting DNA damage on tumour cells, there is increasing interest in the use of inhibitors of DNA repair to increase the cytotoxicity of these agents.
Chalmers, Anthony J
core   +2 more sources

The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and CDKN2A deletion: Direction for third-line patient therapy. [PDF]

, 2017
The aim of the present study was to determine the usefulness of a patient-derived orthotopic xenograft (PDOX) nude-mouse model of a doxorubicin-resistant metastatic Ewing's sarcoma, with a unique combination of a FUS-ERG fusion and CDKN2A deletion, to ...
Bouvet, Michael, Chishima, Takashi, Dry, Sarah M, Eckardt, Mark A, Eilber, Fritz C, Elliott, Irmina A, Endo, Itaru, Hiroshima, Yukihiko, Hoffman, Robert M, Igarashi, Kentaro, Kawaguchi, Kei, Kiyuna, Tasuku, Li, Yunfeng, Matsuyama, Ryusei, Miyake, Kentaro, Miyake, Masuyo, Momiyama, Masashi, Murakami, Takashi, Nelson, Scott D, Russell, Tara A, Singh, Arun S   +20 more
core   +1 more source

Medical treatment of early stage and rare histological variants of epithelial ovarian cancer [PDF]

, 2015
Epithelial ovarian cancer is often considered a single pathological entity, but increasing evidence suggests that it is rather a group of different neoplasms, each with unique pathological characteristics, molecular features, and clinical behaviours ...
Biglia, Nicoletta, CODACCI PISANELLI, Giovanni, Colombo, Nicoletta, Cont, Nicoletta Tomasi, D'Alonzo, Marta, Ferrero, Annamaria, Peccatori, Fedro Alessandro   +6 more
core   +3 more sources